Stock Track | CytomX Therapeutics Plunges 6.92% Pre-Market Following Disappointing Q3 Earnings

Stock Track11-07

CytomX Therapeutics (NASDAQ: CTMX) saw its stock price plummet 6.92% in pre-market trading following the release of its disappointing third-quarter 2025 financial results. The biotech company's earnings and revenue figures fell significantly short of analyst expectations, triggering concern among investors.

The company reported a quarterly loss of $0.09 per share, missing the analyst consensus estimate of $0.05 by a wide margin. This represents a substantial decline from the $0.07 per share earnings reported in the same period last year. Revenue for the quarter came in at $5.96 million, falling well below the analyst estimate of $11.63 million and marking an 82.2% decrease compared to the $33.43 million reported in the previous year's quarter.

Despite the disappointing results, CytomX Therapeutics maintains a solid cash position, reporting $143.6 million in cash, cash equivalents, and investments at the end of the third quarter. The company expects this to provide a runway through the second quarter of 2027. CytomX attributes the revenue decline to the completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities. Looking ahead, the company plans to provide a CX-2051 Phase 1 data update in Q1 2026 and start a CX-2051 Phase 1b CRC study with bevacizumab in the same quarter, which could potentially impact future performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139114147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 17:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139114147","market":"nz","top_or_hot":-1,"title":"Stock Track | CytomX Therapeutics Plunges 6.92% Pre-Market Following Disappointing Q3 Earnings","media":"Stock Track","content":"<p>CytomX Therapeutics (NASDAQ: CTMX) saw its stock price plummet 6.92% in pre-market trading following the release of its disappointing third-quarter 2025 financial results. The biotech company's earnings and revenue figures fell significantly short of analyst expectations, triggering concern among investors.</p>\n\n<p>The company reported a quarterly loss of $0.09 per share, missing the analyst consensus estimate of $0.05 by a wide margin. This represents a substantial decline from the $0.07 per share earnings reported in the same period last year. Revenue for the quarter came in at $5.96 million, falling well below the analyst estimate of $11.63 million and marking an 82.2% decrease compared to the $33.43 million reported in the previous year's quarter.</p>\n\n<p>Despite the disappointing results, CytomX Therapeutics maintains a solid cash position, reporting $143.6 million in cash, cash equivalents, and investments at the end of the third quarter. The company expects this to provide a runway through the second quarter of 2027. CytomX attributes the revenue decline to the completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities. Looking ahead, the company plans to provide a CX-2051 Phase 1 data update in Q1 2026 and start a CX-2051 Phase 1b CRC study with bevacizumab in the same quarter, which could potentially impact future performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CytomX Therapeutics Plunges 6.92% Pre-Market Following Disappointing Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CytomX Therapeutics Plunges 6.92% Pre-Market Following Disappointing Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 17:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CytomX Therapeutics (NASDAQ: CTMX) saw its stock price plummet 6.92% in pre-market trading following the release of its disappointing third-quarter 2025 financial results. The biotech company's earnings and revenue figures fell significantly short of analyst expectations, triggering concern among investors.</p>\n\n<p>The company reported a quarterly loss of $0.09 per share, missing the analyst consensus estimate of $0.05 by a wide margin. This represents a substantial decline from the $0.07 per share earnings reported in the same period last year. Revenue for the quarter came in at $5.96 million, falling well below the analyst estimate of $11.63 million and marking an 82.2% decrease compared to the $33.43 million reported in the previous year's quarter.</p>\n\n<p>Despite the disappointing results, CytomX Therapeutics maintains a solid cash position, reporting $143.6 million in cash, cash equivalents, and investments at the end of the third quarter. The company expects this to provide a runway through the second quarter of 2027. CytomX attributes the revenue decline to the completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities. Looking ahead, the company plans to provide a CX-2051 Phase 1 data update in Q1 2026 and start a CX-2051 Phase 1b CRC study with bevacizumab in the same quarter, which could potentially impact future performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTMX","symbol_name":"CytomX","start_time":0,"source_url":"","article_id":"1139114147","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139114147","pubTimestamp":1762508322,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CytomX Therapeutics (NASDAQ: CTMX) saw its stock price plummet 6.92% in pre-market trading following the release of its disappointing third-quarter 2025 financial results. The biotech company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTMX":"CytomX"},"translate_title":"个股追踪|CytomX Therapeutics第三季度财报令人失望盘前暴跌6.92%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1},"content_text":"CytomX Therapeutics (NASDAQ: CTMX) saw its stock price plummet 6.92% in pre-market trading following the release of its disappointing third-quarter 2025 financial results. The biotech company's earnings and revenue figures fell significantly short of analyst expectations, triggering concern among investors.\nThe company reported a quarterly loss of $0.09 per share, missing the analyst consensus estimate of $0.05 by a wide margin. This represents a substantial decline from the $0.07 per share earnings reported in the same period last year. Revenue for the quarter came in at $5.96 million, falling well below the analyst estimate of $11.63 million and marking an 82.2% decrease compared to the $33.43 million reported in the previous year's quarter.\nDespite the disappointing results, CytomX Therapeutics maintains a solid cash position, reporting $143.6 million in cash, cash equivalents, and investments at the end of the third quarter. The company expects this to provide a runway through the second quarter of 2027. CytomX attributes the revenue decline to the completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities. Looking ahead, the company plans to provide a CX-2051 Phase 1 data update in Q1 2026 and start a CX-2051 Phase 1b CRC study with bevacizumab in the same quarter, which could potentially impact future performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139114147","isCrawlerRequest":true}